The initial wave of Generative AI excitement in the life sciences is meeting a sobering reality: the “Implementation Gauntlet.” While the potential for AI to revolutionize the DMTA cycle is undisputed, many organizations remain trapped in “Pilot Purgatory,” unable to scale individual successes into enterprise-wide impact.
Our latest whitepaper, “From Hype to Implementation,” deconstructs this narrative. We move beyond the 95% failure rate cited in broader enterprise AI to examine why biopharma is different—and what CSOs and Directors of Discovery must do to ensure their digital transformation yields clinical candidates, not just case studies.
Key strategic insights included in the report:
- Archetypal Analysis: A deep dive into the Venture Creation model vs. the Collaborative Outreach model (featuring Eli Lilly’s TuneLab).
- The Data Foundation: Transitioning from fragmented silos to AI-ready strategic assets.
- Agentic AI: Why the industry is moving toward autonomous AI agents to manage complex R&D workflows.
For leadership in Biology, Chemistry, and Informatics, the question is no longer if AI should be used, but how to architect the platform that supports it.
Watch a short explainer video
Download the full whitepaper here.
Interested in discussing how these models apply to your pipeline? Contact our team for a strategic consultation at info@aspen.bio